Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions

A technology of paracrine and paracrine polypeptides, which is applied in the fields of cell and molecular biology and medicine, and can solve the problems of shutting down transgene expression, not being able to treat heart disease, and not being able to regulate transgenes, etc.

Active Publication Date: 2014-12-17
RGT UNIV OF CALIFORNIA
View PDF38 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However: 1) this protein is not under regulated expression and, therefore, cannot optimally regulate the level of the transgene in serum; 2) this system does not provide a means to switch off transgene expression in the event of an expected effect; and 3) the gene, Factor IX, is not a paracrine gene and does not have beneficial cardiovascular effects, and therefore, cannot be used to treat heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
  • Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
  • Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0158] Example 1: Intravenous delivery of AAV9 encoding urocortin-2 enhances cardiac function in normal mice

[0159] This example demonstrates the effectiveness of an exemplary embodiment of the invention: intravenous delivery of AAV9 / urocortin-2 (or AAV9 / UCn2) resulted in sustained increases in serum UCn2 and LV systolic function, demonstrating this exemplary embodiment of the invention. Effectiveness of a sexual embodiment in the treatment of heart failure.

[0160] In this study, we developed and tested the relative efficacy of two adeno-associated virus (AAV) serotypes (AAV5 and AAV9) encoding urocortin-2 (UCn-2), which -2 is a vasoactive peptide in the corticotropin-releasing factor family with diverse beneficial effects in animals and patients with heart failure. AAV5.Ucn-2 and AAV9.Ucn-2 (5×10 11 genome copies, gc). At four weeks (wk) after gene transfer, AAV DNA (qPCR) in liver (AAV5.UCn2: 2,601,839 copies / μg; AAV9.UCn2: 30,121,663 copies / μg) and heart (AAV5: 87,...

Embodiment 2

[0162] Example 2: Gene transfer for the treatment of cardiovascular disease

[0163] This example demonstrates the effectiveness of an exemplary embodiment of the invention in obtaining high yields of transgene expression in the heart in a manner that can be easily and safely administered.

[0164] In alternative embodiments, the invention provides methods of using expression vehicles (eg, vectors) encoding paracrine transgenes. In this embodiment, the transgene acts as a hormone and has a cardiac effect after release into the circulation from a distant site. In an alternative embodiment, this approach could circumvent the problem of achieving high yields of cardiac gene transfer and allow patients to be treated by systemic injection during office visits.

[0165] We tested multiple AAV serotype vectors and delivery methods and successfully completed a proof-of-concept study of paracrine gene transfer. Rats with severe dilated CHF received skeletal muscle delivery of an ad...

Embodiment 3

[0240] Example 3: Delivery of AAV8 Encoding Urocortin-2 Enhances Cardiac Function

[0241] This example demonstrates that in an alternative embodiment of the method of the invention, the paracrine transgene acts as a hormone and has a cardiac effect after being released into the circulation from a distant site. This exemplary approach circumvents the problem of achieving high yields of cardiac gene transfer and enables patients to be treated by systemic injection during office visits. Furthermore, this exemplary approach can eliminate the need for intravenous (IV) delivery of therapeutic peptides and thereby avoid repeated and prolonged hospitalizations, high morbidity, and substantial economic costs. In alternative embodiments, the most suitable vector to achieve these goals is adeno-associated virus type 8 (AAV8), which provides long-term and broad expression.

[0242] In an alternative embodiment of the method, urocortin-2, a recently discovered vasoactive peptide of th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition responsive to an increased or a sustained paracrine polypeptide level in vivo comprising: providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a paracrine-encoding nucleic acid, gene, transcript or message, and the expression vehicle, vector, recombinant virus, or equivalent can express the paracrine-encoding nucleic acid, gene, transcript or message in a cell or in vivo; and administering or delivering the paracrine polypeptide-encoding nucleic acid, gene, transcript or message operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to an individual or a patient in need thereof, thereby treating, ameliorating or protecting (preventing) the individual or patient against the disease, infection or condition responsive to an increased paracrine polypeptide level.

Description

[0001] Statement Regarding Rights to Invention Made Pursuant to Federally Sponsored Research [0002] This invention was made with government support under Grant No. HL088426 awarded by DHHS from the National Institutes of Health (NIH). The government has certain rights in this invention. technical field [0003] The present invention relates to cellular and molecular biology and medicine. The invention provides compositions and in vitro and ex vivo methods. In alternative embodiments, the present invention provides methods for treating, ameliorating or preventing (preventing) a disease, infection or condition in an individual or patient responsive to elevated or sustained levels of a paracrine polypeptide in vivo, the method Including: providing a nucleic acid or gene encoding a paracrine polypeptide operably linked to a transcriptional regulatory sequence; or an expression carrier (vehicle), vector, recombinant virus or Equivalents, and said expression vehicles, vectors, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61K38/17A61K38/16A61K9/08A61K9/06A61P17/00A61P9/00
CPCA61K38/2221A61K38/2242A61K38/25A61K38/30A61K38/52C07K14/57509C07K14/65C12N15/86A61K48/005C12N2750/14143C12N2830/003A61K47/6901A61K31/436A61K31/65A61K38/2228A61P1/16A61P1/18A61P11/00A61P13/12A61P17/00A61P21/00A61P25/00A61P3/04A61P31/00A61P31/04A61P35/00A61P43/00A61P9/00A61P9/04A61P9/12A61P3/10A61K48/00C07K14/075C12N15/861C12N2710/10343A61K9/06A61K9/08A61K38/16A61K38/17A61K2121/00C12N15/8645
Inventor H·K·哈蒙德高美华
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com